Vertex Pharmaceuticals | Home
WEBVertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.
Vertex Pharmaceuticals - Wikipedia
WEBVertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Vertex Pharmaceuticals | Our Company
WEBVertex Pharmaceuticals strikes at the core of serious diseases to change people's lives – learn about our mission, values and recognition.
Vertex Pharmaceuticals Incorporated (VRTX) - Yahoo Finance
WEBFind the latest Vertex Pharmaceuticals Incorporated (VRTX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Vertex Pharmaceuticals | Our Science | R&D Pipeline
WEBVertex Pharmaceuticals is focused on discovering, developing and producing innovative medicines so people with serious diseases can lead better lives.
Vertex Pharmaceuticals | Our Locations
WEBVertex Pharmaceuticals has research and development sites, manufacturing facilities, headquarters and regional offices around the world.
Press Release - Vertex Pharmaceuticals Newsroom
WEBDec 8, 2023 · Vertex leads global development, manufacturing and commercialization of CASGEVY with support from CRISPR Therapeutics. In conjunction with the FDA approval of CASGEVY, Vertex will make a $200 million milestone payment to CRISPR, which will be capitalized and amortized to cost of sales.
Press Release - Vertex Pharmaceuticals Newsroom
WEBNov 16, 2023 · The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases.
Vertex Pharmaceuticals - LinkedIn
WEBAug 10, 2014 · Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and...
Press Release - Vertex Pharmaceuticals Newsroom
WEBMar 21, 2024 · VX-407 is a first-in-class small molecule corrector that is designed to target the underlying cause of ADPKD in a subset of patients with PKD1 variants, estimated at ~25,000 (or ~10%) of the overall ~250,000 ADPKD patient population, by restoring function to the variant PC1 protein.
- Some results have been removed